Create Biomarker Confidence with Tissue Context
Flagship’s cTA® Platform and Decision Support Process accelerates your biomarker-driven drug development strategies.
A comprehensive catalog of more than 100 singleplex and multiplex brightfield immunohistochemistry assays that provide actionable data to define and advance your biomarker program.
Rapidly evaluate existing targets through trend analysis, tissue wide expression and relative rank ordering. Accelerate and simplify your current and future tissue analysis needs.
Flagship Biosciences Accelerates Your Path to Clinical Success
Discovery & PhI Trials
Make informed early pipeline decisions that will accelerate the right clinical path.
Enable critical go/no-go decisions based on confirmation of action.
PhII - PhIII Trials
Solve critical problems in experimental medicine that pose barriers to success.
Differentiate your commercial strategy and increase probability of success.
Meeting the challenges of biomarkers
73% of oncology compounds rely on biomarker data during development, with the scientific challenges of biomarker identification and test development being the most challenging.
Drug Development Support
TARGET VALIDATION & HYPOTHESIS GENERATION
Flagship’s scientific strategy creates a confident path forward for your drug development strategies.
EXPLORATORY & EFFICACY ENDPOINTS
Flagship’s technology creates clear data for confident decisions to direct your drug development programs.
PREDICTIVE STRATEGY BUILDING
Flagship’s clinical and regulatory operations support an accelerated companion diagnostic strategy.
Directly create a diagnostic product to enable a differentiated commercial strategy using our technology.
SOLVE DIFFICULT TISSUE ANALYSIS CHALLENGES WITH OUR UNIQUE APPROACH
Work With Us
Breadth and depth in people and technology to deliver on any challenge
Work With Us